New eczema pill shows promise in early trial

NCT ID NCT07298395

Recruiting now Symptom relief Sponsor: Enveda Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This study tests whether a new oral drug called ENV-294 can safely reduce eczema severity in adults with moderate-to-severe atopic dermatitis. Sixty participants will take either ENV-294 or a placebo pill daily for 12 weeks. Researchers will measure changes in skin symptoms and track any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ENV-294
What this could lead to: If it works, this could point toward a new daily pill to ease eczema symptoms and reduce skin severity.
What could go wrong: This is an early Phase 2 trial with only 60 people. The drug may not work better than placebo, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS (AD)

Contacts and locations

Locations

Enveda Investigative Site
RECRUITING

Birmingham, Alabama, 35244, United States
Enveda Investigative Site
RECRUITING

Hot Springs, Arkansas, 71913, United States
Enveda Investigative Site
RECRUITING

Beverly Hills, California, 90212, United States
Enveda Investigative Site
RECRUITING

Fremont, California, 94538, United States
Enveda Investigative Site
RECRUITING

San Diego, California, 92121, United States
Enveda Investigative Site
RECRUITING

San Diego, California, 92123, United States
Enveda Investigative Site
RECRUITING

Santa Monica, California, 90403, United States
Enveda Investigative Site
RECRUITING

West Hills, California, 91307, United States
Enveda Investigative Site
RECRUITING

Fort Lauderdale, Florida, 33308, United States
Enveda Investigative Site
RECRUITING

Miami, Florida, 33175, United States
Enveda Investigative Site
RECRUITING

Miramar, Florida, 33027, United States
Enveda Investigative Site
RECRUITING

Atlanta, Georgia, 30327, United States
Enveda Investigative Site
RECRUITING

Chicago, Illinois, 60657, United States
Enveda Investigative Site
RECRUITING

Clarksville, Indiana, 47129, United States
Enveda Investigative Site
RECRUITING

New Albany, Indiana, 47150, United States
Enveda Investigative Site
RECRUITING

West Lafayette, Indiana, 47906, United States
Enveda Investigative Site
RECRUITING

Louisville, Kentucky, 40217, United States
Enveda Investigative Site
RECRUITING

Louisville, Kentucky, 40241, United States
Enveda Investigative Site
RECRUITING

Auburn Hills, Michigan, 48326, United States
Enveda Investigative Site
RECRUITING

Bay City, Michigan, 48706, United States
Enveda Investigative Site
RECRUITING

Clinton Township, Michigan, 48038, United States
Enveda Investigative Site
RECRUITING

Warren, Michigan, 48088, United States
Enveda Investigative Site
RECRUITING

Las Vegas, Nevada, 89145, United States
Enveda Investigative Site
RECRUITING

New York, New York, 10029, United States
Enveda Investigative Site
RECRUITING

Wilmington, North Carolina, 28405, United States
Enveda Investigative Site
RECRUITING

Canton, Ohio, 44718, United States
Enveda Investigative Site
RECRUITING

Mayfield Heights, Ohio, 44124, United States
Enveda Investigative Site
RECRUITING

Camp Hill, Pennsylvania, 17011, United States
Enveda Investigative Site
RECRUITING

Arlington, Texas, 76011, United States
Enveda Investigative Site
RECRUITING

Houston, Texas, 77004, United States
Enveda Investigative Site
RECRUITING

San Antonio, Texas, 78218, United States
Enveda Investigative Site
RECRUITING

Norfolk, Virginia, 23502, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.